×
BeiGene Inventory 2014-2024 | ONC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BeiGene inventory for the quarter ending September 30, 2024 was
$0.432B
, a
36.21% increase
year-over-year.
BeiGene inventory for 2023 was
$0.416B
, a
47.38% increase
from 2022.
BeiGene inventory for 2022 was
$0.282B
, a
16.37% increase
from 2021.
BeiGene inventory for 2021 was
$0.243B
, a
171.72% increase
from 2020.
View More
BeiGene Inventory 2014-2024 | ONC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BeiGene inventory for 2023 was
$0.416B
, a
47.38% increase
from 2022.
BeiGene inventory for 2022 was
$0.282B
, a
16.37% increase
from 2021.
BeiGene inventory for 2021 was
$0.243B
, a
171.72% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$160.1B
Vertex Pharmaceuticals (VRTX)
$123.9B
Gilead Sciences (GILD)
$122.2B
Bristol Myers Squibb (BMY)
$116.5B
CSL (CSLLY)
$82.8B
Regeneron Pharmaceuticals (REGN)
$79.3B
GSK (GSK)
$75.4B
Argenex SE (ARGX)
$40B
Alnylam Pharmaceuticals (ALNY)
$35.9B
BioNTech SE (BNTX)
$28.8B
Biogen (BIIB)
$20.7B
Illumina (ILMN)
$19.5B
Insmed (INSM)
$14.5B
Incyte (INCY)
$14.4B
Intra-Cellular Therapies (ITCI)
$13.5B
Moderna (MRNA)
$12.9B
Genmab (GMAB)
$12.8B
Genmab (GNMSF)
$12.7B
BioMarin Pharmaceutical (BMRN)
$12.3B
Bio-Techne Corp (TECH)
$11.9B
Vaxcyte (PCVX)
$11.1B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Sarepta Therapeutics (SRPT)
$10.7B
Exact Sciences (EXAS)
$10B
Bio-Rad Laboratories (BIO.B)
$9.6B
Exelixis (EXEL)
$9.6B
QIAGEN (QGEN)
$9.4B
Repligen (RGEN)
$9.1B
Roivant Sciences (ROIV)
$7.9B
Ascendis Pharma (ASND)
$7.6B